Biogen Announces Positive Phase 1 Results, Plan to License and Develop Ionis Pharmaceuticals' Investigational Therapy BIIB067 for Familial ALS - Muscular Dystrophy Association
Ionis Pharmaceuticals Inc (IONS) News Today - StockEarnings.com
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA | Biogen
Akcea and Ionis Receive FDA Approval of TEGSEDI™
Projected Growth of Severe Hypertriglyceridemia Market
Ionis Pharmaceuticals, Inc. sur LinkedIn : #ionis
Ionis on X: "Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia. Read the press release here: https://t.co/nC2SkQuKoA #antisense $IONS https://t.co/hprPaX8TEi" / X
Ionis to seek FDA approval of donidalorsen after positive trial data
Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx | Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. on LinkedIn: #antisense #ionisintern #internship #interns #research
Ionis Names Company Co-Founder as New COO, Effective Jan. 15, 2018 | BioSpace
RNA-directed therapeutics at Ionis
Ionis Pharmaceuticals, Inc. (IONS) Stock Price, Quote & News - Stock Analysis
PCSK9 Inhibitor Pipeline Insights Report 2023 (Updated) | Ionis
IONIS Press Release Causes More Questions and Concerns
RG6042 Huntingtin-Lowering Trial History | Huntington Society of Canada
Ionis Pharmaceuticals (IONS) Stock Latest News - IONS News Today
Ionis Pharmaceuticals plans large expansion in Carlsbad - The San Diego Union-Tribune
Contact | Ionis Pharmaceuticals, Inc.
Press Releases | Ionis Pharmaceuticals, Inc.
Ionis Launches Phase 3 Trial of Donidalorsen for Preventing HAE Attacks
Investors & Media | Ionis Pharmaceuticals, Inc.
IONIS Press Release Causes More Questions and Concerns
With FDA approval, Ionis and AstraZeneca gear up to launch rare disease drug Wainua | Fierce Pharma
Investors & Media | Ionis Pharmaceuticals, Inc.
Jamie Morgan on LinkedIn: Ionis announces positive olezarsen topline results from Phase 3 study in…
IONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington'
Ionis Pharmaceuticals Inc (IONS) News Today - StockEarnings.com
